SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a draft guidance for industry entitled “Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling.” This draft guidance provides recommendations on: (1) When pharmacokinetic studies in patients with hepatic impairments are or are not recommended; (2) the design and conduct of studies to characterize the effects of impaired hepatic function on the pharmacokinetics of a drug; (3) characteristics of patient populations to be studied; (4) analysis, interpretation, and reporting of the results of the studies; and (5) the description of study results in drug labeling.

The draft guidance reflects the current view that the liver generally plays an important role in the elimination (metabolism and/or excretion) of a drug and that the effect of hepatic impairment on the elimination of a new drug should generally be defined during drug development.

This level 1 draft guidance is being issued consistent with FDA’s good guidance practices (62 FR 8961, February 27, 1997). The draft guidance represents the agency’s current thinking on pharmacokinetic studies in patients with impaired hepatic function. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both.

Interested persons may, on or before February 7, 2000, submit to the Dockets Management Branch (address above) written comments on the draft guidance. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The draft guidance and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: November 30, 1999.

Margaret M. Dotzel,
Acting Associate Commissioner for Policy.
[FR Doc. 99–31608 Filed 12–6–99; 8:45 am]
BILLING CODE 4160–01–F